Selexipag Impurities

veeprho banner
Parent Drug Name Name of Impurity Catalogue No.
Selexipag Selexipag DPA Des-Isopropyl Impurity VL4020001View
Selexipag Selexipag DPB Desisopropyl Impurity VL4020002View CAS 2514706-51-3
Selexipag Selexipag Impurity B VL4020005View CAS 18591-57-6
Selexipag Selexipag In-house Impurity C VL4020006View CAS 41270-66-0
Selexipag Selexipag Metabolite N-Oxide VE0011194View CAS 2732400-56-3
Selexipag Selexipag Pyrazinone Impurity VE0011192View CAS 18591-57-6
Selexipag Selexipag TDA Impurity VL4020004View CAS 162928-03-2
Selexipag 2-Chloro-5, 6-diphenylpyrazine VE0011193View CAS 41270-66-0
Selexipag 4-[(5, 6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-butanol VE0010267View CAS 475086-75-0

Selexipag Related Compound

Selexipag is a medication used to treat the symptoms of pulmonary arterial hypertension, which is excessive blood pressure in the primary artery that transports blood from the right side of the heart (the ventricle) to the lungs.

References

FAQ

Does selexipag act as a vasodilator?

Selexipag is a prostacyclin receptor agonist that produces pulmonary vasodilation and is used to treat pulmonary arterial hypertension (PAH).

What purpose does selexipag serve?

Selexipag is used to treat pulmonary hypertension (pulmonary arterial hypertension-PAH). It is used to assist delay the progression of PAH and reduce the likelihood of hospitalization. Selexipag works by increasing the flow of blood through the arteries in your lungs.

Does selexipag contain prostacyclins?

Selexipag is an orally administered, selective prostacyclin receptor agonist used to treat pulmonary arterial hypertension.

[rfq_list]

Request a quote

162928-03-2: Selexipag TDA Impurity

162928-03-2: Selexipag TDA Impurity
Catalogue No.

VL4020004

CAS No.

162928-03-2

Molecular Formula

C22H22N2O3

Molecular Weight

362.42

Parent drug

Selexipag

IUPAC Name

Tert-butyl 2-((5, 6-diphenylpyrazin-2-yl)oxy)acetate;

Synonyms

Selexipag O Impurity

References

Coghlan, J. Gerry, et al. “Selexipag in the Management of Pulmonary Arterial Hypertension: An Update.” Drug, Healthcare and Patient Safety, vol. Volume 11, Aug. 2019, pp. 55–64, https://doi.org/10.2147/dhps.s181313. ?

Status

In-stock

ListName

Selexipag TDA Impurity

Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden